Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
BMC Cancer|May 14, 2009
Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: inverse correlation between HYAL1 and hyaluronan contentTimo K Nykopp, Kirsi Rilla, Reijo Sironen, et al.
Cancer Research|November 20, 2002
Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumorsEssi L J Hiltunen, Maarit Anttila, Anne Kultti, et al.
European Radiology|March 15, 2017
Primary and metastatic ovarian cancer: Characterization by 3.0T diffusion-weighted MRIAuni Lindgren, Maarit Anttila, Suvi Rautiainen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 4, 2008
Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in miceHanna Sallinen, Maarit Anttila, Johanna Narvainen, et al.
Frontiers in Medicine|December 26, 2022
AAV8-mediated sVEGFR2 and sVEGFR3 gene therapy combined with chemotherapy reduces the growth and microvasculature of human ovarian cancer and prolongs the survival in miceAnni Kujala, Elina Valkonen, Hanna Sallinen, et al.
Human Gene Therapy. Clinical Development|May 23, 2013
Preclinical safety, toxicology, and biodistribution study of adenoviral gene therapy with sVEGFR-2 and sVEGFR-3 combined with chemotherapy for ovarian cancerLaura Tuppurainen, Hanna Sallinen, Emmi Kokki, et al.
International Journal of Cancer|February 17, 2012
Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinomaMinna Sopo, Maarit Anttila, Hanna Sallinen, et al.
Breast Cancer Research and Treatment|July 14, 2011
Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibilityMikko Vuorela, Katri Pylkäs, Jaana M Hartikainen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 9, 2023
PErsonalized TReatment for Endometrial Carcinoma (PETREC): study design and methods of a prospective Finnish multicenter trialMikko Loukovaara, Ralf Bützow, Synnöve Staff, et al.
NPJ Vaccines|August 16, 2025
Proteogenomic approach to immunopeptidomics of ovarian tumors identifies shared peptide vaccine candidatesJacopo Chiaro, Karita Peltonen, Kadri Õunap, et al.
Pageof 6